A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and feasibility of BXT-51072 as a
cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous
intervention (PCI), a procedure to "open" coronary arteries.
BXT-51072 belongs to a class of drugs called "glutathione peroxidase mimics." BXT-51072 works
by imitating a substance produced in various tissues in the body, which prevents damage of
the heart and blood vessels.